Half of respondents who outsource cell and/or gene manufacturing activities to CDMOs are outsourcing process development to ensure the ability to scale-up manufacturing should the therapy advance towards commercialization. Respondents from large biopharma companies are slightly more likely to outsource this activity in the near future when compared to respondents from nonlarge biopharma companies (52% vs 45%).
View Resource